drugset / Trial / NCT06148311
Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia
Phase 2
Enrolling by invitation
15 enrolled
NYU Langone Health
Food and Drug Administration (FDA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this placebo controlled interventional study is to collect preliminary data on administering dexmedetomidine in patients with Familial Dysautonomia (FD) during a rapid cessation of autonomic crisis. The primary aims are to assess the feasibility and evaluate if measurements of heart rate, blood pressure and oxygen saturation can predict the start of an autonomic crisis. Funding Source- FDA OOPD
Timeline
- Start
- 2024-07-01
- Primary completion
- 2027-01-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 120 ug | Other |